Innovent Announces the First Phase 3 Clinical Trial of Mazdu

Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

ROCKVILLE, Md. and SUZHOU, China, Jan. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Related Keywords

China , Hong Kong , United States , Macau , Peking , Beijing , Taiwan , Suzhou , Jiangsu , Chinese , Adimab Incyte , Innovent Biologics , Linong Ji , Eli Lilly , China National Medical Products Administration , Global Health Data Exchange , Clinical Development Of Innovent , University People Hospital , Incyte Corporation , Company Lilly , Institute For Health Metrics , Prnewswire Innovent Biologics Inc , Md Anderson Cancer Center , Drug Evaluation , National Medical Products Administration , Peking University People , Lei Qian , Vice President , Clinical Development , Cancer Center , Mainland China , Lancet Diabetes Endocrinol , Health Metrics , Global Health Data , Markets ,